A Market Shaping Approach for the Biopharmaceutical Industry: Governing Innovation Towards the Public Interest
Abstract
Enhancing research and development and ensuring equitable pricing and access to cutting-edge treatments are both vital to a biopharmaceutical innovation system that works in the public interest. However, despite delivering numerous therapeutic advances, the existing system suffers from major problems: a lack of directionality to meet key needs, inefficient collaboration, high prices that fail to reflect the public contribution, and an overly-financialized business model.Other Versions
No versions found
My notes
Similar books and articles
Considerations for applying bioethics norms to a biopharmaceutical industry setting.Wendell Fortson,Kathleen Novak Stern,Curtis Chang,Angela Rossetti,Ariella Kelman,Michael Turik,Donald G. Therasse,Tatjana Poplazarova &Luann E. Van Campen -2021 -BMC Medical Ethics 22 (1).
“A Most Equitable Drug”: How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug Development.Quinn Grundy,Chantal Campbell,Ridwaanah Ali,Matthew Herder &Kelly Holloway -2024 -Journal of Law, Medicine and Ethics 52 (1):80-97.
Rethinking Innovation in Drugs: A Pathway to Health for All.Mariana Mazzucato -2023 -Journal of Law, Medicine and Ethics 51 (S2):16-20.
The Government and Pharmaceutical Innovation: Looking Back and Looking Ahead.Bhaven N. Sampat -2021 -Journal of Law, Medicine and Ethics 49 (1):10-18.
Incentivizing access and innovation for essential medicines: A survey of the problem and proposed solutions.Michael Ravvin -2008 -Public Health Ethics 1 (2):110-123.
Two Birds with One Stone: The Quest for Addressing Both Business Goals and Social Needs with Innovation.Marina Candi,Monia Melia &Maria Colurcio -2018 -Journal of Business Ethics 160 (4):1019-1033.
Needs‐Driven Versus Market‐Driven Pharmaceutical Innovation: The Consortium for the Development of a New Medicine against Malaria in Brazil.Koichi Kameda -2014 -Developing World Bioethics 14 (2):101-108.
Digital Literacy as a Tool for Addressing Inequities in the Indian Education System.Prabaharan Manoj -2024 -Journal of Science Technology and Research (JSTAR) 5 (1):520-528.
Biopharmaceutical Innovation Capacities – Benchmarking Europe and Implications for CEE.Sibylle Gaisser &Thomas Reiss -2008 -Law and Ethics of Human Rights 2 (2).
Use of Public Research and Manufacturing Enterprises to Lower Prescription Drug Prices and Increase Innovation.Alex Moss,Dana Brown &S. Sean Tu -2024 -Journal of Law, Medicine and Ethics 52 (3):750-754.
Analytics
Added to PP
2021-04-22
Downloads
32 (#784,163)
6 months
4 (#1,010,049)
2021-04-22
Downloads
32 (#784,163)
6 months
4 (#1,010,049)
Historical graph of downloads
How can I increase my downloads?Citations of this work
INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development — Historical Scope, Opportunities, and Challenges.Ameet Sarpatwari &Aaron S. Kesselheim -2021 -Journal of Law, Medicine and Ethics 49 (1):6-9.
References found in this work
The Pharmaceutical Commons: Sharing and Exclusion in Global Health Drug Development.Catherine M. Montgomery &Javier Lezaun -2015 -Science, Technology, and Human Values 40 (1):3-29.
What Will It Take to Address the Global Threat of Antibiotic Resistance?Steven J. Hoffman &Kevin Outterson -2015 -Journal of Law, Medicine and Ethics 43 (2):363-368.
Home |New books and articles |Bibliographies |Philosophy journals |About PhilPapers |API |Contact us |Code of conduct
PhilPapers logo byAndrea Andrews andMeghan Driscoll.
This site uses cookies and Google Analytics (see ourterms & conditions for details regarding the privacy implications).Use of this site is subject toterms & conditions.
All rights reserved byThe PhilPapers Foundation
Server: philpapers-web-54b44b69b7-sq5lk uwo